Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Biotech Inc.

Division of Johnson & Johnson
www.janssenbiotech.com

Latest From Janssen Biotech Inc.

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Advances On the Biosimilar Litigation Battlefield

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Biosimilars Intellectual Property

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data

The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.
Commercial Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register